The recommendation will allow more data to be collected about the combination treatment while allowing patients with high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer to access the medication.
List view / Grid view
The Scottish Medicines Consortium (SMC) has rejected Kalydeco (ivacaftor) and Orkambi (lumacaftor-ivacaftor) for the treatment of cystic fibrosis.
17 June 2013 | By Roche
First approval of Avastin for the treatment of newly diagnosed glioblastoma...
Roche’s medicine Avastin plus chemotherapy improved survival in women with advanced cervical cancer, compared to chemotherapy alone
2 June 2013 | By Roche
Results of study GOG240...